Skip to main content
SpringerLink
Log in
Book cover

Psychiatrie der Gegenwart 5 pp 495–531Cite as

Pharmakotherapie affektiver Störungen

  • Chapter

  • 119 Accesses

Zusammenfassung

Die Pharmakotherapie affektiver Störungen hat zu umwälzenden Veränderungen im Krankheitsverlauf dieser Störungsbilder geführt und hat ganz entscheidende Verbesserungen hinsichtlich der sozialen Rolle betroffener Patienten wie auch der gesundheitsökonomischen Belastung der Gesellschaft mit sich gebracht. Der Einsatz einer medikamentösen Behandlung erhöht signifikant die Chance, daß sich ein depressiver Patient innerhalb von 3–6 Wochen wieder erholen wird. Die Pharmakotherapie kann aber nicht unabhängig von einer tragfähigen Arzt-Patient-Beziehung und dem gemeinsamen Verstehen der Erkrankung gesehen werden. Eine therapeutische Allianz dient nicht nur der Veminderung einer unzureichenden Compliance von Patienten, sondern erleichtert es auch, die möglicherweise auftretenden medikamentösen Nebenwirkungen und die zu erwartende Latenzzeit bis zum Ansprechen auf die Behandlung ausführlich zu besprechen sowie den Stellenwert der medikamentösen Behandlung und ihre voraussichtliche Dauer im Kontext eines Gesamt-behandlungsplanes klarzumachen.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Adler L, Hajak G, Lehmann K et al. (1997) On the problems of switching from intravenous to oral administration in drug treatment of endogenous depression Pharmacopsychiatry 30: 62–69

    CAS  Google Scholar 

  • Akiskal HS (1994) Dysthymic and cyclothymic depressions: therapeutic considerations. J Clin Psychiatry 55 (Suppl 4): 46–52

    PubMed  Google Scholar 

  • *Amsterdam JD, Hornig Rohan M (1996) Treatment algorithms in treatment-resistant depression Psychiatr Clin North Am 19: 371–386

    CAS  Google Scholar 

  • Asberg M (1976) Treatment of depression with tricyclic drugs — pharmacokinetic and pharmacodynamic aspects. Pharmacopsychiatry Neuropsychopharmacol 9: 18–26

    CAS  Google Scholar 

  • Baldessarini RJ, Tohen M (1988) Is there a long-term protective effect of mood-altering agents in unipolar depressive disorder? Psychopharmacol Ser 5: 130–139

    PubMed  CAS  Google Scholar 

  • Barondes SH (1994) Thinking about Prozac. Science 263 (515O): 1102–1103

    Article  PubMed  CAS  Google Scholar 

  • Bauer M, Whybrow P (1990) Rapid cycling bipolar affective disorder: treatment of refractory rapid cycling with high dose levothyroxine: a preliminary study. Arch Gen Psychiatry 47: 435–440

    PubMed  CAS  Google Scholar 

  • Bloch RG, Dooneief AS, Buchberg AS et al. (1954) The clinical effects of isoniazid and iproniazid in the treatment of pulmonary tuberculosis. Ann Intern Med 40: 881–900

    PubMed  CAS  Google Scholar 

  • Bouchard JM, Strub N, Nil R (1997) Citalopram and viloxazine in the treatment of depression by slow drop infusion. A double-blind comparative trial. J Affect Disord 46 /1: 51–58

    Article  PubMed  CAS  Google Scholar 

  • *Bowden CL (1996) Dosing strategies and time course of response to antimanic drugs. J Clin Psychiatry 57 (Suppl 13): 4–12

    PubMed  CAS  Google Scholar 

  • Bowden CL, Brugger AM, Swann AC et al. (1994) Efficacy of divalproex versus lithium and placebo in the treatment of mania. JAMA 271: 918–924

    Article  PubMed  CAS  Google Scholar 

  • Burke MJ, Silkey B, Preskorn SH (1994) Pharmacoeconomic considerations when evaluating treatment options for major depressive disorder. J Clin Psychiatry 55 (Suppl A): 42–52

    PubMed  Google Scholar 

  • Calabrese JR, Kimmel SE, Woyshville M J et al. (1996) Clozapine for treatment-refractory mania. Am J Psychiatry 153 /6: 759–764

    PubMed  CAS  Google Scholar 

  • Chaimowitz GA, Links PS, Padgett RW, Carr AC (1991) Treatment-resistant depression: a survey of practice habits of Canadian psychiatrists. Can J Psychiatry 36: 353–356

    PubMed  CAS  Google Scholar 

  • Chouinard G, Young SN, Annable L (1983) Antimanic effects of clonazepam. Biol Psychiatry 18: 451–466

    PubMed  CAS  Google Scholar 

  • Cohen LJ (1997) Rational drug use in the treatment of depression. Pharmacotherapy 17: 45–61

    PubMed  CAS  Google Scholar 

  • Dardennes R, Even C, Bange F et al. (1995) Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorders. A meta-analysis. Br J Psychiatry 166: 378–381

    Article  PubMed  CAS  Google Scholar 

  • Denicoff KD, Earlian E, Smith-Jackson RN et al. (1997) Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder. Am J Psychiatry 154: 1456–1458

    PubMed  CAS  Google Scholar 

  • Doogan DP, Caillard V (1992) Sertraline in the prevention of depression. Br J Psychiatry 160: 217–222

    Article  PubMed  CAS  Google Scholar 

  • *Expert Consensus Guidelines (1996) Guidelines for the treatment of bipolar affective disorder. J Clin Psychiatry 57(Suppl 12A)7–42

    Google Scholar 

  • Garza-Trevino ES, Overall JE, Hollister LE (1992) Verapamil versus lithium in acute mania. Am J Psychiatry 149: 121–127

    PubMed  CAS  Google Scholar 

  • Gastpar M, Gilsdorf U, Baumann P (1986) Comparison of oral and intravenous treatment of depressive states: preliminary results of a WHO collaborative study. Clin Neuropharmacol 9: 434–436

    PubMed  Google Scholar 

  • *Gelenberg AJ, Hopkins HS (1996) Antipsychotics in bipolar disorder. J Clin Psychiatry 57 (Suppl 9): 49–52

    PubMed  Google Scholar 

  • Gelenberg AJ, Carroll JA, Baudhuin MG et al. (1989) The meaning of serum lithium levels in maintenance therapy of mood disorders: a review of the literature. J Clin Psychiatry 50 (Suppl 12): 17–22

    PubMed  Google Scholar 

  • Guelfi JD, White C, Hackett D et al. (1995) Effectiveness of venlafaxine in patients hospitalised for major depression and melancholia. J Clin Psychiatry 56: 450–458

    PubMed  CAS  Google Scholar 

  • Hirschfeld RM, Schatzberg AF (1994) Long-term management of depression. Am J Med 97:33s–38s

    Google Scholar 

  • Hotopf M, Lewis G, Normand C et al. (1996) Are SSRIs a cost-effective alternative to tricyclics? Br J Psychiatry 168: 404–409

    Article  PubMed  CAS  Google Scholar 

  • Howland RH (1990) Pharmacotherapy of dysthymia: a review. J Clin Psychopharmacol 11: 83–92

    Google Scholar 

  • Howland RH, Thase ME (1993) A comprehensive review of cyclothymic disorder. J Nerv Ment Dis 181: 485–493

    Article  PubMed  CAS  Google Scholar 

  • Joffe (1998) The use of thyroid supplements to augment antidepressant medication. J Clin Psychiatry 59 (Suppl 5): 26–29

    PubMed  CAS  Google Scholar 

  • Joffe RT, Singer W, Levitt AJ et al. (1993) A placebo-controlled comparison of lithium and triiodo-thyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 50 /5: 387–393

    PubMed  CAS  Google Scholar 

  • Jonsson B, Bebbington PE (1993) What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 164: 665–673

    Article  Google Scholar 

  • Katona CLE, Abou-Saleh MT, Harrison DA et al. (1995) Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 166 /1: 80–86

    Article  PubMed  CAS  Google Scholar 

  • Kragh-Sorensen P, Asberg M, Eggert-Hansen C (1973) Plasma-nortryptiline levels in endogenous depression. Lancet 1: 113–115

    Article  PubMed  CAS  Google Scholar 

  • Kuhn R (1958) The treatment of depressive states with G22355 (imipramine hydrochloride). Am J Psychiatry 115: 459–464

    PubMed  CAS  Google Scholar 

  • *Kupfer DJ, Frank E, Perel JM et al. (1992) Five year outcome for maintenance therapies in recurrent depression Arch Gen Psychiatry 49: 769–773

    CAS  Google Scholar 

  • Lam RW, Stewart JN (1996) The validity of atypical depression in DSM-IV. Compr Psychiatry 37: 375–383

    Article  PubMed  CAS  Google Scholar 

  • Laux G (1993) Antidepressive Infusionstherapie. In: Riederer P, Law G (Hrsg) Neuropsychopharmaka, vol 3. Springer, Berlin Heidelberg New York Tokio, S 257–268

    Google Scholar 

  • Laux G, Konig W, Lesch K et al. (1989) Intravenose versus orale Behandlung endogen depressiver Patienten mit Doxepin — eine Doppelblindstudie mit Plasma-spiegelbestimmungen. Wien Med Wochenschr 22: 525–529

    Google Scholar 

  • Lonnqvist J, Sivho S, Syvalahti E et al. (1994) Moclobemide and flouxetine in atypical depression: a double blind trial. J Affect Disord 32 /3: 169–177

    Article  PubMed  CAS  Google Scholar 

  • *McElroy SL, Keck PE, Pope HG et al. (1992) Valproate in the treatment of bipolar disorder: literature review and clinical guidelines. J Clin Psychopharmacol 12(Suppl 1)425–525

    Google Scholar 

  • McElroy SL, Keck PE, Strakowski SM (1996) Mania, psychosis and antipsychotics. J Clin Psychiatry 57 (Suppl 3): 14–26

    PubMed  Google Scholar 

  • Moller HJ, Volz HP (1996) Drug treatment of depression in the 1990s. An overview of achievements and future possibilities. Drugs 52: 625–638

    Article  PubMed  CAS  Google Scholar 

  • Montgomery SA, Dunbar G (1993) Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 8: 189–195

    Article  PubMed  CAS  Google Scholar 

  • *Nemeroff CB, DeVane CL, Pollock BG (1996) Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 153: 311–320

    PubMed  CAS  Google Scholar 

  • Nierenberg AA (1991) Treatment choice after one antidepressant fails: a survey of Northeastern psychiatrists. J Clin Psychiatry 52: 383–385

    PubMed  CAS  Google Scholar 

  • Nierenberg AA (1994) The treatment of severe depression: is there an efficacy gap between SSRI and TCA antidepressant generations? J Clin Psychiatry 55(Suppl A):55– 59

    Google Scholar 

  • Nierenberg AA, White K (1990) What next? A review of pharmacologic strategies for treatment resistant depression. Psychopharmacol Bull 26: 429–460

    PubMed  CAS  Google Scholar 

  • Nierenberg AA, Feighner JP, Rudolph R et al. (1994) Venlafaxine for treatment resistant unipolar depression. J Clin Psychopharmacol 14: 419–423

    Article  PubMed  CAS  Google Scholar 

  • Oren DA, Rosenthal NE (1992) Seasonal affective disorders. In: Paykel ES (ed) Handbook of affective disorders. Churchill Livingstone, Edinburgh

    Google Scholar 

  • *Peet M (1994) Induction of mania with selective serotonin reuptake inhibitors and tricyclic antidepressants. Br J Psychiatry 164: 549–550

    Article  PubMed  Google Scholar 

  • Perry PJ (1996) Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. J Affect Disord 39: 1–6

    Article  PubMed  CAS  Google Scholar 

  • Pollock B, Perei JM, Nathan R et al. (1989) Acute antidepressant effect following pulse loading with intravenous and oral clomipramine. Arch Gen Psychiatry 46: 29–35

    PubMed  CAS  Google Scholar 

  • Post RM, Uhde TW, Roy-Byrne PP et al. (1987) Correlates of antimanic response to carbamazepine. Psychiatry Res 21: 71–83

    Article  PubMed  CAS  Google Scholar 

  • Post RM, Denicoff KD, Frye MA et al. (1997) Re-evaluating carbamazepine prophylaxis in bipolar disorder. Br J Psychiatry 170: 202–204

    Google Scholar 

  • *Prien RF (1992) Maintenance treatment. In: Paykel ES (ed) Handbook of affective disorders. Churchill Livingstone, Edinburgh, pp 419–435

    Google Scholar 

  • Prien RF, Kupfer DJ (1986) Continuation drug therapy for major depressive disorder: how long should it be maintained? Am J Psychiatry 143: 18–23

    PubMed  CAS  Google Scholar 

  • Prien RF, Rush AJ (1996) National Institute of Mental Health Workshop Report on the treatment of bipolar disorder. Biol Psychiatry 40: 215–220

    Article  PubMed  CAS  Google Scholar 

  • Priest RG (1996) Cost-effectiveness of venlafaxine for the treatment of major depression in hospitalized patients. Clin Ther 18: 347–358

    Article  PubMed  CAS  Google Scholar 

  • Quitkin FM (1985) The importance of dosage in prescribing antidepressants. Br J Psychiatry 147: 593–597

    Article  PubMed  CAS  Google Scholar 

  • *Richelson E (1996) Synaptic effects of antidepressants. J Clin Psychopharmacol 16:1s–7s

    Google Scholar 

  • Roose SP, Glassman AH, Walsh BT et al. (1986) Tricyclic non-responders: phenomenology and treatment. Am J Psychiatry 143: 345–348

    PubMed  CAS  Google Scholar 

  • *Sachs GS (1996) Treatment-resistant bipolar depression. Psychiatr Clin North Am 19: 215–236

    Article  PubMed  CAS  Google Scholar 

  • Sanger T, Tohen M, Tollefson G et al. (1998) Olanzapine vs placebo in the treatment of acute mania. Schizophr Res 29/1, 2: 152

    Google Scholar 

  • Sansone RA, Sansone LA (1996) Dysthymic disorder: the depression that never quits. Postgrad Med 99: 233–234

    PubMed  CAS  Google Scholar 

  • Schaffer C, Schaffer L (1997) Gabapentin in the treatment of bipolar disorder. Am J Psychiatry 154: 291–292

    PubMed  CAS  Google Scholar 

  • Schou M (1990) Lithium treatment during pregnancy, delivery and lactation: an update. J Clin Psychiatry 51: 410–413

    PubMed  CAS  Google Scholar 

  • *Schou M (1997) Forty years of lithium treatment. Arch Gen Psychiatry 54: 9–13

    PubMed  Google Scholar 

  • Sclar DA, Robison LM, Skaer TL et al. (1994) Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Clin Ther 16: 715–730

    PubMed  CAS  Google Scholar 

  • Sclar DA, Robison LM, Skaer TL et al. (1995) Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization. J Int Med Res 23: 395–412

    PubMed  CAS  Google Scholar 

  • Shergill SS, Katona CLE (1997) Pharmacological choices after one antidepressant fails. J Affect Disord 43: 19–25

    Article  PubMed  CAS  Google Scholar 

  • Sporn J, Sachs G (1997) The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness. J Clin Psychopharmacol 17: 185–189

    Article  PubMed  CAS  Google Scholar 

  • Sternbach H (1991) The serotonin syndrome. Am J Psychiatry 148: 705–713

    PubMed  CAS  Google Scholar 

  • *Stoddart G, Drummond M (1984) How to read clinical journals. VII. To understand an economic evaluation. Can Med Assoc J 130: 1428–1433

    Google Scholar 

  • Sunderland T, Cohen RM, Molchan SE et al. (1994) High-dose selegiline in treatment-resistant older depressive patients. Arch Gen Psychiatry 51: 607–615

    PubMed  CAS  Google Scholar 

  • Task Force on the Use of Laboratory Tests in Psychiatry (1985) Tricyclic antidepressants — blood level measurements and clinical outcome: an APA Task Force report. Am J Psychiatry 142: 155–162

    Google Scholar 

  • Wehr TA, Goodwin FK (1987) Can antidepressants cause mania and worsen the course of affective illness? Am J Psychiatry 144: 1403–1411

    PubMed  CAS  Google Scholar 

  • World Psychiatric Association Dysthymia Working Group (1995) Dysthymia in clinical practice. Br J Psychiatry 166: 174–183

    Article  Google Scholar 

  • Wright G, Galloway L, Kim J et al. (1985) Bupropion in the long-term treatment of cyclic mood disorders: mood stabilising effects. J Clin Psychiatry 46: 22–25

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. S. S. Shergill
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. L. E. Katona
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psychiatrische Klinik, Freie Universität Berlin, Eschenallee 3, D-14050, Berlin, Germany

    Hanfried Helmchen

  2. Klinikum rechts der Isar, Technische Universität Müchen, Ismaninger Str. 22, D-81675, München, Germany

    Hans Lauter

  3. Zentralinstitut für Seelische Gesundheit, Postfach 12 21 20, D-68072, Mannheim, Germany

    Fritz Henn

  4. Hôpitaux Universitaires de Genève, Belle-Idée, Bâtiment Salève 2, chemin du Petit-Bel-Air, CH-1225, Chêne-Bourg/Genève, Switzerland

    Norman Sartorius

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Shergill, S.S., Katona, C.L.E. (2000). Pharmakotherapie affektiver Störungen. In: Helmchen, H., Lauter, H., Henn, F., Sartorius, N. (eds) Psychiatrie der Gegenwart 5. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59626-1_23

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-59626-1_23

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-64057-5

  • Online ISBN: 978-3-642-59626-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation